Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 5/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | Q9HBH1 | 1/20 | 0.38 | |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.36 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | FURIN | P09958 | 2/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.33 |
| ▸ | TGM2 | P21980 | 1/20 | 0.33 |
| ▸ | NPY1R | P25929 | 1/20 | 0.33 |
| ▸ | NPY2R | P49146 | 1/20 | 0.33 |
| ▸ | NPY4R | P50391 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17178689 | 1.00 | FAP (0.44) | FAPHTR2APDFMAP1LC3BSSTR3 | |
| SCHEMBL18391329 | 1.00 | FAP (0.44) | FAPHTR2APDFMAP1LC3BSSTR3 | |
| SCHEMBL12442419 | 1.00 | FAP (0.44) | FAPHTR2APDFMAP1LC3BSSTR3 | |
| SCHEMBL3205376 | 1.00 | FAP (0.44) | FAPHTR2APDFMAP1LC3BSSTR3 | |
| SCHEMBL3798438 | 1.00 | FAP (0.44) | FAPHTR2APDFMAP1LC3BSSTR3 | |
| SCHEMBL12441917 | 1.00 | FAP (0.44) | FAPHTR2APDFMAP1LC3BSSTR3 | |
| Water SCHEMBL30811226 | 0.99 | FAP (0.43) | FAPHTR2APDFMAP1LC3BSSTR3 | |
| SCHEMBL15189371 | 0.97 | FAP (0.41) | FAPHTR2APDFMAP1LC3BSSTR3 | |
| SCHEMBL29983999 | 0.96 | FAP (0.41) | FAPHTR2APDFSSTR3ALDH1A1 | |
| SCHEMBL23493270 | 0.96 | HTR2A (0.43) | FAPHTR2APDFMAP1LC3BSSTR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2357006-A2 | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease | Seattle Genetics, Inc. (US) | 2011-08-17 | — | — | EP | disclosed |
| EP-2353611-A2 | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease | Seattle Genetics, Inc. (US) | 2011-08-10 | — | — | EP | disclosed |
| US-20110064753-A1 | DRUG CONJUGATES AND THEIR USE FOR TREATING CANCER, AN AUTOIMMUNE DISEASE OR AN INFECTIOUS DISEASE | SEATTLE GENETICS, INC. (US) | 2011-03-17 | — | — | US | disclosed |
| US-7851437-B2 | monoclonal antibody conjugated with peptide drug such as dolastatin derivative | SEATTLE GENETICS INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851437-B2 | monoclonal antibody conjugated with peptide drug such as dolastatin derivative | SEATTLE GENETICS INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-7829531-B2 | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease | SEATTLE GENETICS INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-7829531-B2 | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease | SEATTLE GENETICS INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20100062008-A1 | monoclonal antibody conjugated with peptide drug such as dolastatin derivative | SEATTLE GENETICS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| US-20100062008-A1 | monoclonal antibody conjugated with peptide drug such as dolastatin derivative | SEATTLE GENETICS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| US-7659241-B2 | monoclonal antibody conjugated with peptide drug such as dolastatin derivative | SEATTLE GENETICS, INC. (US) | 2010-02-09 | — | — | US | disclosed |
| US-20090324621-A1 | monoclonal antibody conjugated with peptide drug such as dolastatin derivative | SEATTLE GENETICS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090324621-A1 | monoclonal antibody conjugated with peptide drug such as dolastatin derivative | SEATTLE GENETICS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110064753-A1 | DRUG CONJUGATES AND THEIR USE FOR TREATING CANCER, AN AUTOIMMUNE DISEASE OR AN INFECTIOUS DISEASE | CD47, CD2, CD22 | FAP 1308/4885HTR2A 3642/4885PDF 423/4885 |
| US-20100062008-A1 | monoclonal antibody conjugated with peptide drug such as dolastatin derivative | DAD1, DDOST, STT3A | FAP 2680/4885HTR2A 4624/4885PDF 69/4885 |
| US-20090324621-A1 | monoclonal antibody conjugated with peptide drug such as dolastatin derivative | DAD1, DDOST, STT3A | FAP 2680/4885HTR2A 4624/4885PDF 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.